JP2013509861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509861A5 JP2013509861A5 JP2012536757A JP2012536757A JP2013509861A5 JP 2013509861 A5 JP2013509861 A5 JP 2013509861A5 JP 2012536757 A JP2012536757 A JP 2012536757A JP 2012536757 A JP2012536757 A JP 2012536757A JP 2013509861 A5 JP2013509861 A5 JP 2013509861A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding polypeptide
- her3
- her3 binding
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 34
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 208000029986 neuroepithelioma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09175025 | 2009-11-04 | ||
| EP09175025.7 | 2009-11-04 | ||
| PCT/SE2010/051164 WO2011056124A1 (en) | 2009-11-04 | 2010-10-27 | Her3 binding polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013509861A JP2013509861A (ja) | 2013-03-21 |
| JP2013509861A5 true JP2013509861A5 (https=) | 2013-12-05 |
| JP5960598B2 JP5960598B2 (ja) | 2016-08-02 |
Family
ID=43302000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012536757A Expired - Fee Related JP5960598B2 (ja) | 2009-11-04 | 2010-10-27 | Ｈｅｒ３結合ポリペプチド |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10208128B2 (https=) |
| EP (1) | EP2496598B1 (https=) |
| JP (1) | JP5960598B2 (https=) |
| WO (1) | WO2011056124A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694139C (en) * | 2007-07-31 | 2018-06-05 | Affibody Ab | Albumin binding polypeptide compositions |
| US20120165650A1 (en) * | 2010-12-22 | 2012-06-28 | General Electric Company | Her2 binders |
| MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| CN104768571B (zh) | 2012-07-13 | 2018-11-09 | 酵活有限公司 | 多价异多聚体支架设计和构建体 |
| US9745350B2 (en) | 2012-10-05 | 2017-08-29 | Affibody Ab | HER3 binding polypeptides |
| AU2013336646B2 (en) | 2012-10-25 | 2016-07-14 | Affibody Ab | ABD binding polypeptide |
| PL2912051T3 (pl) | 2012-10-25 | 2018-08-31 | Affibody Ab | Sposób rozdzielania białek zawierających domenę wiążącą albuminę |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| EP2935335B1 (en) * | 2012-12-19 | 2020-10-28 | Affibody AB | New polypeptides |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| ES2660912T3 (es) * | 2013-03-15 | 2018-03-26 | Affibody Ab | Nuevos polipéptidos |
| MX367423B (es) * | 2013-08-28 | 2019-08-21 | Affibody Ab | Polipeptidos de union a c5. |
| HRP20250551T1 (hr) | 2013-11-27 | 2025-06-20 | Zymeworks Bc Inc. | Bispecifični antigen-vezujući konstrukti koji ciljaju her2 |
| IL301147A (en) | 2014-02-28 | 2023-05-01 | Merus Nv | An antibody that binds to ErbB-2 and ErbB-3 |
| EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| MX2016014862A (es) * | 2014-05-14 | 2017-02-27 | Hoffmann La Roche | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. |
| SI3193930T1 (sl) * | 2014-09-17 | 2019-10-30 | Affibody Ab | Novi polipeptidi |
| US12428483B2 (en) * | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| SG11201704741PA (en) * | 2014-12-22 | 2017-07-28 | Systimmune Inc | Bispecific tetravalent antibodies and methods of makiing and using thereof |
| WO2017008169A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus B.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
| WO2018212656A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| CN118580366A (zh) | 2017-08-09 | 2024-09-03 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
| TW202416938A (zh) | 2022-08-10 | 2024-05-01 | 日商興和股份有限公司 | 親和體微胞(affibody micelle)藥物複合體 |
| JP2025542406A (ja) * | 2022-12-30 | 2025-12-25 | アブクロン・インコーポレイテッド | Ｃｄ１３７に特異的に結合するアフィボディ及びその用途 |
| EP4694978A1 (en) * | 2023-04-11 | 2026-02-18 | Antaros Tracer AB | Drug delivery systems |
| WO2024227930A1 (en) * | 2023-05-04 | 2024-11-07 | Affibody Ab | New polypeptide |
| GB202318674D0 (en) * | 2023-12-06 | 2024-01-17 | Oncopeptides Ab | Novel polypeptides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7993650B2 (en) * | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
| JP5634008B2 (ja) | 2004-04-06 | 2014-12-03 | アフィボディ・アーベー | 新規の使用および方法 |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| SG178789A1 (en) * | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| EP2183275B1 (en) | 2007-08-03 | 2014-10-29 | Affibody AB | Igf-1r binding polypeptides and their use |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| US9745350B2 (en) | 2012-10-05 | 2017-08-29 | Affibody Ab | HER3 binding polypeptides |
| CN117442748A (zh) * | 2014-10-02 | 2024-01-26 | 希望之城公司 | 多价中间表位、中间表位结合抗体及其用途 |
-
2010
- 2010-10-27 EP EP10775936.7A patent/EP2496598B1/en active Active
- 2010-10-27 JP JP2012536757A patent/JP5960598B2/ja not_active Expired - Fee Related
- 2010-10-27 US US13/505,493 patent/US10208128B2/en active Active
- 2010-10-27 WO PCT/SE2010/051164 patent/WO2011056124A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509861A5 (https=) | ||
| KR102236829B1 (ko) | 헵시딘 유사체 및 이의 용도 | |
| JP2014508510A5 (https=) | ||
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| NZ603623A (en) | Tcr complex immunotherapeutics | |
| MX2012007850A (es) | Composiciones y metodo para tratar gliobastoma (gbm). | |
| HRP20110551T1 (hr) | Antagonisti cikličkog peptida cxcr4 | |
| JP2013506411A5 (https=) | ||
| US20170281796A1 (en) | c-Met Antibody Drug Conjugate | |
| JP2016521257A5 (https=) | ||
| EA201291362A1 (ru) | Слитый белок против злокачественных новообразований | |
| EA200901430A1 (ru) | Варианты фермента аспарагиназы и их применение | |
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| WO2013184960A3 (en) | Chimeric fibroblast growth factor 23 proteins and methods of use | |
| JP2017006120A5 (https=) | ||
| RU2014143639A (ru) | Регулируемые протеазой антитела | |
| JP2013172743A5 (https=) | ||
| MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
| WO2007123765A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
| CN104342444B (zh) | 一种重组trail蛋白及其制备方法和用途 | |
| RU2015141932A (ru) | Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| KR102399024B1 (ko) | 신규 폴리펩티드 | |
| WO2013185241A1 (en) | Aptamers specific to cea and tnf-alpha and their therapeutic uses | |
| CN105985447B (zh) | 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |